One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
-
Patent number: 10960077Abstract: A liquid or semi-solid matrix or magma or paste which is non-newtonian, thixotropic and pseudoplastic and composed of one or more controlled release agent, and/or one or more clays such as bentonite and/or one or more fillers in a non aqueous vehicle, and optionally materials selected from disintegrants, humectants, surfactants and stabilizers. The composition and physicochemical properties makes it harder or prevents dose dumping of narcotic analgesics in the presence of alcohol and harder to abuse opiod agonists or narcotic analgesics and discourages drug abuse via crushing, milling or grinding the dosage form to powder or heating the dosage form to vapour and snorting or inhalation by the nasal route or dissolving to abuse via the parenteral route.Type: GrantFiled: May 12, 2006Date of Patent: March 30, 2021Assignee: Intellipharmaceutics Corp.Inventors: Isa Odidi, Amina Odidi
-
Patent number: 10925870Abstract: Disclosed is a method for reducing or preventing fetal opioid dependence in a drug dependent or opioid tolerant pregnant subject. The method involves administering to the pregnant subject a composition comprising an opioid antagonist in an amount effective to reduce or prevent fetal opioid dependence, wherein the opioid antagonist a) is orally available or delivered systemically and reaches the circulation of the pregnant subject, b) is substantially excluded from the subject's brain by the blood brain barrier, and c) penetrates the placenta and enters the fetal brain. The method also includes administering the opioid antagonist to the neonate in increasing amounts to facilitate weaning the neonate from continued opioid maintenance.Type: GrantFiled: January 6, 2017Date of Patent: February 23, 2021Assignee: Ohio State Innovation FoundationInventors: Wolfgang Sadee, John Oberdick
-
Patent number: 10870654Abstract: Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.Type: GrantFiled: March 18, 2019Date of Patent: December 22, 2020Assignee: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
-
Patent number: 10865186Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.Type: GrantFiled: August 22, 2018Date of Patent: December 15, 2020Assignee: Nektar TherapeuticsInventors: Franco J. Duarte, Neel K. Anand, Pankaj Sharma, Devendrapratap Singh
-
Patent number: 10828294Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.Type: GrantFiled: March 18, 2019Date of Patent: November 10, 2020Assignee: Nalpropion Pharmaceuticals LLCInventors: Preston Klassen, Kristin Taylor
-
Patent number: 10806731Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .Type: GrantFiled: April 25, 2019Date of Patent: October 20, 2020Assignee: Alkermes Pharma Ireland LimitedInventors: Daniel R. Deaver, Elliot Ehrich
-
Patent number: 10799545Abstract: Transdermal delivery devices for the delivery of cannabidiol (CBD) and related moieties are shown and described. In a reservoir-patch design, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent, along with other moieties that seem to be enhanced or bioavailability of increased by the same. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In using CBD as a pure compound or as one to combine with other moieties, the invention is able to control delivery better than the prior art. Construction of the transdermal patch of reservoir type is also taught, which enables things such as Vitamin B12 to become part of the complex deliverable by the inventions.Type: GrantFiled: April 29, 2019Date of Patent: October 13, 2020Assignee: Remy Biosciences, Inc.Inventor: Ludwig Weimann
-
Patent number: 10744132Abstract: An injectable pharmaceutical composition includes a solution of 3-acyl-buprenorphine, or a pharmaceutically acceptable salt thereof, in a biocompatible organic solvent, wherein the injectable pharmaceutical composition exhibits a steady release profile lasting over one week when injected into a patient. The acyl group is an alkylcarbonyl group, and an alkyl portion of the alkylcarbonyl group is a straight-chain, branched-chain, having 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone, ethyl acetate, ethanol, butanol, 2-butanol, isobutanol, ispropanol, glycerin, benzyl benzoate, dimethyl sulfoxide, N,N-dimethylacetamide, propylene glycol, dimethyl glycol, benzyl alcohol, or a combination of two or more thereof.Type: GrantFiled: September 12, 2017Date of Patent: August 18, 2020Assignee: Alar Pharmaceuticals, Inc.Inventors: Tong-Ho Lin, Yung-Shun Wen, Jui-Wei Liang
-
Patent number: 10702480Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.Type: GrantFiled: May 9, 2014Date of Patent: July 7, 2020Assignee: OHEMO Life Sciences, Inc.Inventors: Manish S. Shah, Ray J. DiFalco
-
Patent number: 10695324Abstract: The present invention generally relates to a method of treating or preventing an endoplasmic reticulum stress disorder in subjects, such as a method of treating or preventing Wolfram syndrome.Type: GrantFiled: September 30, 2019Date of Patent: June 30, 2020Assignee: Washington UniversityInventors: Fumihiko Urano, Simin Lu
-
Patent number: 10695342Abstract: Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.Type: GrantFiled: February 13, 2017Date of Patent: June 30, 2020Assignees: ALBANY MOLECULAR RESEARCH, INC., 3ST RESEARCH LLCInventors: Matthew Surman, John K. Thottathil, Kathryn Golden, Paolo Pasetto, Xiaomin Jin, Xiaowu Jiang, Fatoumata Camara
-
Patent number: 10696684Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: November 20, 2019Date of Patent: June 30, 2020Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P, RHODES TECHNOLOGIESInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Patent number: 10695343Abstract: A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.Type: GrantFiled: October 8, 2018Date of Patent: June 30, 2020Inventors: Noreen Griffin, Fengping Shan, Nicholas Plotnikoff
-
Patent number: 10689389Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: August 30, 2019Date of Patent: June 23, 2020Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIESInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Patent number: 10653632Abstract: The present disclosure relates generally to binder powders for use in powder material processing and processes for their preparation. The disclosure further relates to binder powders for use in making solid powder compact forms, solid powder compact forms containing said binder powders and methods for making solid powder compact forms.Type: GrantFiled: February 28, 2012Date of Patent: May 19, 2020Assignee: Monash UniversityInventors: David Morton, Laurence Orlando, Tony Qi Zhou, Louise Chia-Hua Ho
-
Patent number: 10638786Abstract: Methods and compositions are provided directed to decreasing visceral fat in subjects. Visceral fat is directly linked to cardiovascular and metabolic disease risk. The methods describe a calorie restricted diet of specific percentages of food elements to be consumed within a specific time period each day. Calorie restriction and nutrient percentages take into consideration average daily normal activity of subjects as well as baseline health metrics including estimated amount of visceral fat. Remarkable results are obtained since visceral fat is targeted for reduction, thereby markedly reducing the risk of cardiovascular and metabolic disease.Type: GrantFiled: August 16, 2017Date of Patent: May 5, 2020Assignee: Zolighter, LLCInventors: Jessica Barnes, Gerald Dembrowski
-
Patent number: 10632205Abstract: A pharmaceutical paste composition comprising an active ingredient such as an addictive substance, a controlled release agent, and a pharmaceutically suitable aqueous or non-aqueous carrier. The composition may comprise one or more of a clay, or an oily, waxy, or fatty substance. The composition may be filled into a capsule or other dispensing device. The composition may reduce dose dumping of an active ingredient. Methods of making and using the composition are also described.Type: GrantFiled: May 29, 2015Date of Patent: April 28, 2020Assignee: INTELLIPHARMACEUTICS CORPInventors: Isa Odidi, Amina Odidi
-
Patent number: 10604488Abstract: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.Type: GrantFiled: September 2, 2016Date of Patent: March 31, 2020Assignee: Mallinckrodt LLCInventors: Bobby N. Trawick, David W. Berberich, Christopher W. Grote
-
Patent number: 10588973Abstract: The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promotor. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component.Type: GrantFiled: April 23, 2018Date of Patent: March 17, 2020Assignee: MEDRx Co., LTDInventors: Yasushi Miwa, Hidetoshi Hamamoto, Naoya Akazawa
-
Patent number: 10576045Abstract: The present invention provides a pharmaceutical composition comprising a selective serotonin reuptake inhibitor (SSRI) and a norepinephrine reuptake inhibitor (NRI), particularly, fluoxetine and reboxetine, for treating obesity. Surprisingly, the inventor of the present invention discovered that use of especially low doses of the active compounds, particularly, at most 6 mg/day of reboxetine and at most 20 mg/day of fluoxetine, wherein the reboxetinerfluoxetine ratio is from about 1:4 to about 1:6, induces an effective weight loss in obese patients. Advantageously, the combinations of the present invention include very low doses of the active ingredients, thereby decreasing possible drug-drug interactions and adverse drug reaction.Type: GrantFiled: February 15, 2012Date of Patent: March 3, 2020Inventor: Nir Barak
-
Patent number: 10561628Abstract: An object of the present invention is to provide [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate as a stabilized pharmaceutical solid preparation, and also to provide a method for preparing the stabilized pharmaceutical solid preparation. The object can be attained by a pharmaceutical solid preparation comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate which is a compound represented by the following formula (I) in combination with (i) one or two or more excipients, (ii) one or two or more disintegrants, and (iii) a specific antioxidant.Type: GrantFiled: March 17, 2016Date of Patent: February 18, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Shinichiro Tajiri, Jin Hisazumi, Shinji Yoshinaga, Hiroyuki Fujimori, Hiroaki Arai
-
Patent number: 10555916Abstract: A method of treating a pervasive development disorder in a subject includes administering to the subject an amount of an NMDAR antagonist effective to ameliorate biochemical and functional abnormalities in the subject associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein 2 (MeCP2).Type: GrantFiled: January 27, 2014Date of Patent: February 11, 2020Assignee: CASE WESTERN RESERVE UNIVERSITYInventor: David M. Katz
-
Patent number: 10517841Abstract: 5-HT receptor agonists are useful in the treatment of a variety of diseases. Provided herein are methods of treating and/or reducing the occurrence of respiratory depression caused by an opioid in a human patient or patient population using a 5-HT receptor agonist, such as, for example, a 5-HT4 agonist (e.g., fenfluramine). Methods of stimulating one or more 5-HT4 receptors in the brain of a patient undergoing treatment with an opioid, wherein the patient is at risk of respiratory depression, by administering a 5-HT4 agonist (e.g., fenfluramine) to a subject in need thereof are provided. Pharmaceutical compositions for use in practicing the subject methods are also provided.Type: GrantFiled: June 5, 2019Date of Patent: December 31, 2019Assignee: ZOGENIX INTERNATIONAL LIMITEDInventors: Bradley S. Galer, Carl L. Faingold, Parthena Martin
-
Patent number: 10449235Abstract: Some embodiments are directed to the use of creatine kinase or fragments thereof which induce analgesia, and also to the use of pharmaceutical compositions including the same, to relieve pain.Type: GrantFiled: March 7, 2016Date of Patent: October 22, 2019Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE STRASBOURGInventors: Yannick Goumon, Jinane Mouheiche, Alexis Laux-Biehlmann, Pierrick Poisbeau, Nisrine Kamoun
-
Patent number: 10449190Abstract: The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to opioids in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.Type: GrantFiled: March 29, 2017Date of Patent: October 22, 2019Inventor: John K. Thottathil
-
Patent number: 10441585Abstract: Immediate release, oral, pharmaceutical formulation comprising nalbuphine or a pharmaceutically acceptable salt thereof, and at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant.Type: GrantFiled: June 1, 2016Date of Patent: October 15, 2019Assignee: DEBREGEAS ET ASSOCIES PHARMAInventors: Christophe Lebon, Pascal Suplie, David Olivier Paul
-
Patent number: 10441537Abstract: Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated.Type: GrantFiled: May 10, 2018Date of Patent: October 15, 2019Assignee: InCarda Therapeutics, Inc.Inventors: Carlos Schuler, Rangachari Narasimhan, Luiz Belardinelli, Prashanti Madhavapeddi
-
Patent number: 10441657Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.Type: GrantFiled: May 8, 2017Date of Patent: October 15, 2019Assignee: ABUSE DETERRENT PHARMACEUTICALS, LLCInventors: Albert W. Brzeczko, R. Gary Hollenbeck
-
Patent number: 10406153Abstract: The invention is directed to processes for the preparation of benzhydrocodone hydrochloride. More particularly, the invention is directed to processes for a one-pot synthesis of benzhydrocodone hydrochloride of improved yield and/or purity.Type: GrantFiled: August 31, 2017Date of Patent: September 10, 2019Assignee: Noramco, Inc.Inventors: Wen-Chun Zhang, Bruce P. Johnson
-
Patent number: 10403170Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.Type: GrantFiled: April 19, 2017Date of Patent: September 3, 2019Assignee: Nalpropion Pharmaceuticals, Inc.Inventors: Preston Klassen, Kristin Taylor
-
Patent number: 10376584Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.Type: GrantFiled: March 30, 2017Date of Patent: August 13, 2019Assignee: Progenics Pharmaceuticals, Inc.Inventors: Suketu P. Sanghvi, Thomas A. Boyd
-
Patent number: 10370382Abstract: There is provided a novel process for the preparation of a compound of formula (I), wherein R1 is as described in the description, by demethylation of a corresponding O-methyl derivative.Type: GrantFiled: July 26, 2016Date of Patent: August 6, 2019Assignee: Cambrex Charles City, Inc.Inventors: Pär Holmberg, Michael Robert Tracey, Zhiming Eric Dong
-
Patent number: 10351574Abstract: Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.Type: GrantFiled: October 12, 2017Date of Patent: July 16, 2019Assignee: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
-
Patent number: 10314838Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ c ma ? ? x ? ( BUP ) / EC 50 ] [ c ma ? ? x ? ( ANTAGONIST ) / IC 50 ] .Type: GrantFiled: September 28, 2017Date of Patent: June 11, 2019Assignee: Alkermes Pharma Ireland LimitedInventors: Daniel Deaver, Elliot Ehrich
-
Patent number: 10300015Abstract: The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.Type: GrantFiled: June 5, 2014Date of Patent: May 28, 2019Assignee: PharnextInventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Viviane Bertrand
-
Patent number: 10292972Abstract: A pharmaceutical composition containing an anticancer compound, named isopicrinine, isolated from the plant Rhazya Stricta. The pharmaceutical composition may contain a salt, an analog, a derivative, and/or the prodrug of isopicrinine. A method of treating cancer with the pharmaceutical composition is disclosed. A method of extracting isopicrinine is also disclosed.Type: GrantFiled: October 26, 2017Date of Patent: May 21, 2019Assignee: King Abdulaziz UniversityInventors: Jamal Sabir M. Sabir, Abdullah Y. Obaid, Nahid H. Hajrah, Waseem Mohammed, Zainab H. Abdul-Hameed, Walied M. Alarif, Roop Singh Bora, Seif-Eldin N. Ayyad, Nouf Saeed A. Al-Abbas, Abdulkader M. Shaikh Omer, Mohammed Zainy Mutawakil, Neil Hall, Kulvinder Singh Saini
-
Patent number: 10278967Abstract: The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further provides method of preparing the acetate salts, buprenorphine free base prepared from the acetate salts, other salts prepared from the free base, and pharmaceutical compositions thereof essentially free of impurities.Type: GrantFiled: February 12, 2018Date of Patent: May 7, 2019Assignee: Rhodes TechnologiesInventors: C. Frederick M. Huntley, Erik Wayne Kataisto, Helge Alfred Reisch, Archana Sharma
-
Patent number: 10259819Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: September 29, 2017Date of Patent: April 16, 2019Assignees: PURDUE PHARMA L.P., THE P.F. LABORATORIES, INC., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIESInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Patent number: 10258616Abstract: The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain.Type: GrantFiled: November 10, 2017Date of Patent: April 16, 2019Assignee: Euro-Celtique S.A.Inventors: Helen Kathleen Danagher, Hassan Mohammad, Malcolm Walden, Geoffrey Gerard Hayes, Jonathon Oliver Whitehouse, Thinnayam Naganathan Krishnamurthy, Ricardo Alberto Vargas Rincon
-
Patent number: 10258235Abstract: The present invention provides a method for assessing bowel function in a patient, comprising providing the patient with a numeric analog scale for at least one parameter which is a measure of bowel function; causing the patient to indicate on the numeric analog scale the amount and/or intensity of the parameter being experienced; and observing the amount and/or intensity of the at least one parameter indicated on the numeric analog scale in order to assess bowel function.Type: GrantFiled: February 28, 2006Date of Patent: April 16, 2019Assignee: Purdue Pharma L.P.Inventors: Petra Leyendecker, Michael Hopp, Axel Drews
-
Patent number: 10238647Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.Type: GrantFiled: September 26, 2016Date of Patent: March 26, 2019Assignee: Nalpropion Pharmaceuticals, Inc.Inventors: Eckard Weber, Michael Alexander Cowley
-
Patent number: 10226456Abstract: Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.Type: GrantFiled: April 27, 2016Date of Patent: March 12, 2019Assignee: 3ST Research LLCInventor: John K. Thottathil
-
Patent number: 10226457Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.Type: GrantFiled: December 8, 2017Date of Patent: March 12, 2019Assignee: Purdue Pharma L.P.Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
-
Patent number: 10216900Abstract: Information regarding a patient's physiological signs is provided in real-time, in particular in conjunction with drug administration to the patient. A patient data input obtains patient data of a monitored patient. A drug identification input obtains drug administration data identifying a drug administered to the patient and the time of administration of the drug to the patient. A drug information input obtains drug information about the identified drug, including drug side effects and/or drug-drug interactions and/or drug-disease contraindications. A processing unit determines time-resolved monitoring information based on the obtained patient data, drug administration data and drug information. The monitoring information is dynamically adapted and one or more physiological signs of the patient that are most critical to monitor over time are indicated. An output interface outputs the monitoring information.Type: GrantFiled: September 18, 2015Date of Patent: February 26, 2019Assignee: KONINKLIJKE PHILIPS N.V.Inventors: Murtaza Bulut, Charles Frederik Sio
-
Patent number: 10206921Abstract: Methods for treating a central nervous system (CNS) injury in a subject are provided. Aspects of the methods include administering to the subject an effective amount of gamma aminobutyric acid (GABA) receptor signaling inhibitor to treat the subject for the CNS injury. Also provided are compositions finding use in embodiments of the methods. Methods and compositions of the invention find use in the treatment of a variety of different CNS injuries, including but not limited to, treating a subject for CNS injury associated with the occurrence of stroke.Type: GrantFiled: June 3, 2010Date of Patent: February 19, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Stanley T. Carmichael, Istvan Mody, Andrew Clarkson, Ben Huang
-
Patent number: 10201174Abstract: The present invention relates to processes for removal of Michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors and the resulting thiol-Michael adducts. Certain embodiments of the present invention enable quantification and/or removal of Michael acceptors and/or Michael acceptor precursors.Type: GrantFiled: August 1, 2016Date of Patent: February 12, 2019Assignee: Controlled Chemicals, Inc.Inventors: Jules A. Shafer, Vladislav V. Telyatnikov, Hao Wang
-
Patent number: 10201553Abstract: A pharmaceutical composition for the prevention, protective effect, or treatment of a neurodegenerative condition, is provided. The composition includes a combination of cannabidiol water soluble powder; astaxanthin; alpha-glyceryl phosphoryl choline; and phosphatidyl serine. Optional supporting ingredients may be provided also.Type: GrantFiled: July 17, 2017Date of Patent: February 12, 2019Assignee: H Smart Inc.Inventors: Dianna Steinberg, Tim Altvater
-
Patent number: 10195219Abstract: The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities.Type: GrantFiled: April 11, 2014Date of Patent: February 5, 2019Assignee: NED Biosystems, Inc.Inventor: Rebecca Lambert Bent
-
Patent number: 10189852Abstract: Processes for preparing oxymorphone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxymorphinone salt in the presence of trifluoroacetic acid and/or a glycol.Type: GrantFiled: April 3, 2018Date of Patent: January 29, 2019Assignee: RHODES TECHNOLOGIESInventors: Joshua Robert Giguere, Keith Edward McCarthy, Marcel Schleusner
-
Patent number: 10188643Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .Type: GrantFiled: October 2, 2017Date of Patent: January 29, 2019Assignee: Alkermes Pharma Ireland LimitedInventors: Daniel Deaver, Elliot Ehrich